GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (MEX:AZNN) » Definitions » Institutional Ownership

AstraZeneca (MEX:AZNN) Institutional Ownership : 12.25% (As of Dec. 11, 2024)


View and export this data going back to 2007. Start your Free Trial

What is AstraZeneca Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, AstraZeneca's institutional ownership is 12.25%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, AstraZeneca's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, AstraZeneca's Float Percentage Of Total Shares Outstanding is 0.00%.


AstraZeneca Institutional Ownership Historical Data

The historical data trend for AstraZeneca's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Institutional Ownership Chart

AstraZeneca Historical Data

The historical data trend for AstraZeneca can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 12.32 12.48 12.36 12.41 12.73 12.83 12.78 12.38 12.30 12.25

AstraZeneca Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


AstraZeneca Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

AstraZeneca Headlines

No Headlines